The University of Glasgow has an international reputation for innovative research in health.
The institution’s unique partnership with NHS Greater Glasgow and Clyde (NHS GGC) brings together world-leading clinical academics, NHS clinicians and advanced infrastructure at the Queen Elizabeth University Hospital (QEUH) campus.
Recent university investment at the QUEH hub totals more than £70 million, and establishes Glasgow as a world leader in precision medicine
University-led facilities at QEUH include:
•A dedicated 22,000ft Clinical Innovation Zone ─ high-spec units and proximity to academics and clinicians are attracting an expanding array of partner companies.
•Imaging Centre of Excellence (ICE) – including an ultra-high resolution 7 Tesla MRI scanner, the first of its kind fully integrated in a UK clinical site. This UK Science Park accredited facility was awarded the UKSPA 2019 ‘Setting the Pace Award’ to recognise enabling assets, facilities and support as part of this this ever growing life sciences cluster.
•Stratified Medicine Scotland Innovation Centre ─ supporting pioneering, collaborative research and innovation (across universities and businesses) in precision medicine for chronic disease, and managing the Scottish Precision Medicine Ecosystem.
•Clinical Research Facility ─ ensuring the hospital is at the forefront of clinical trials of new medicines in both adult and paediatric medicine.
•Queen Elizabeth Teaching and Learning Centre.
•The MRC/EPSRC-funded Glasgow Molecular Pathology Node, a collaboration between the University and NHS with industry partners (Aridhia Informatics, BioClavis, Illumina, Leica Biosystems, Sistemic and ThermoFisher Scientific ) aimed at increasing the capacity and capability of the UK to drive novel diagnostics to market through provision of integrated support and postgraduate-level training;
•iCAIRD – the Industrial Centre for Artificial Intelligence Research in Digital Diagnostics – resulting from a pan-Scotland consortium led by the University of Glasgow, with funding from partner companies and the Industrial Strategy Challenge Fund. iCAIRD is a collaboration of 15 partners from across academia, the NHS, and industry received £10m funding from the Industrial Strategy Challenge Fund and £6M from Canon Medical Research Europe Ltd and Philips, along with six SMEs. iCAIRD will develop next generation clinical decision support tools or ‘clinical cockpits’ and create new jobs centred around AI and digital technology in healthcare.
Plans are now underway to develop a ‘Living Laboratory’ at the Queen Elizabeth University Hospital to translate innovation into standard clinical practice. The £46M project is one of 23 shortlisted across the UK for UKRI Strength in Places funding and is subject to a full stage application.
The University’s Clinical Innovation Zone at QEUH is part of the developing Glasgow Riverside Innovation District, which extends to the University’s West End campus and provides collaborative space for industry partners, start-ups and spin-outs to work alongside Glasgow’s world class academics.
High-impact research projects with university involvement include:
• PRECISION-Panc trial – advancing personalised medicine treatment strategies for pancreatic cancer, led by University of Glasgow and funded by Cancer Research UK.
• CHART-ADAPT pilot programme ─ supporting improved detection and treatment of brain injury, run by the University of Glasgow, NHS GGC, Philips Healthcare and Aridhia Informatics Ltd.
• Platform technology for precision medicine diagnostics ─by BioClavis, a spinout from Californian molecular profiling company BioSpyder, in collaboration with university researchers and the health service, and based at the Clinical Innovation Zone at the QEUH.
If you would like to reach out to discuss anything from the above case study, please get in touch.
Let us know if you would like to discuss contributing to the case studies we currently profile.